Augmedix (OTCMKTS:AUGX) Upgraded by Zacks Investment Research to Buy

Augmedix (OTCMKTS:AUGXGet Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday, reports. The firm currently has a $2.50 target price on the stock. Zacks Investment Research‘s price objective would suggest a potential upside of 23.76% from the stock’s previous close.

According to Zacks, “Augmedix Inc. is a provider of remote medical documentation and live clinical support. Augmedix Inc. is based in SAN FRANCISCO, Calif. “

Separately, Lake Street Capital assumed coverage on shares of Augmedix in a research note on Monday, March 7th. They issued a “buy” rating and a $6.00 price objective for the company. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $5.90.

Augmedix stock traded down $0.18 during midday trading on Tuesday, hitting $2.02. 30,878 shares of the stock were exchanged, compared to its average volume of 29,753. Augmedix has a 52-week low of $1.95 and a 52-week high of $6.22. The stock has a market capitalization of $75.54 million and a price-to-earnings ratio of -3.37. The business’s 50-day moving average price is $2.68 and its 200-day moving average price is $2.95. The company has a quick ratio of 3.60, a current ratio of 3.04 and a debt-to-equity ratio of 0.66.

Augmedix (OTCMKTS:AUGXGet Rating) last posted its quarterly earnings results on Wednesday, March 30th. The company reported ($0.16) earnings per share (EPS) for the quarter. The business had revenue of $6.58 million during the quarter. Augmedix had a negative net margin of 77.52% and a negative return on equity of 251.74%. On average, sell-side analysts predict that Augmedix will post -0.61 earnings per share for the current fiscal year.

Several hedge funds have recently bought and sold shares of the stock. Boston Partners purchased a new stake in shares of Augmedix during the fourth quarter valued at $290,000. Envestnet Asset Management Inc. purchased a new stake in Augmedix in the fourth quarter valued at approximately $33,000. Northern Trust Corp purchased a new stake in Augmedix in the 4th quarter worth approximately $100,000. Baker Tilly Wealth Management LLC purchased a new stake in Augmedix in the 4th quarter worth approximately $116,000. Finally, Perkins Capital Management Inc. purchased a new stake in Augmedix in the 4th quarter worth approximately $1,351,000. 59.03% of the stock is owned by hedge funds and other institutional investors.

About Augmedix (Get Rating)

Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live and Augmedix Notes solutions that provide pre-visit documentation, such as pre-charting and digitization of previous records/patient history; during-visit documentation, including medical notes, care gap reminders, HCC reminders, and after-visit summaries; and post-visit documentation consisting of coding, orders, and referrals.

See Also

Get a free copy of the Zacks research report on Augmedix (AUGX)

For more information about research offerings from Zacks Investment Research, visit

Analyst Recommendations for Augmedix (OTCMKTS:AUGX)

Receive News & Ratings for Augmedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Augmedix and related companies with's FREE daily email newsletter.